CIBBIM – Nanomedicine. Drug delivery and targeting : VHIR Annual Report 2020

Oncology

< Back

Overview

In 2020, the Area has been composed by eight groups addressing main unsolved issues in cancer, covering the fields of child and adolescent cancer, melanoma, gynecology, urology, cancer stem cells and molecular mechanisms of the tumor pathologies, as well nanomedicine. We work in close collaboration with the corresponding departments at the Hospital. This provides a unique opportunity to tackle the abovementioned pathologies during the entire course of the disease, from diagnosis (a focus and strength of our Area) to personalized treatment (gathering important international impact during 2020 in the field of child cancer). Our research in 2020 has been relevant also in the field of the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics. Despite, the COVID-19 pandemic, the Area has kept active at virtual shared activities and ONCO-VHIR seminars and the organization of the World Cancer Day event to get closer to the society. During 2020 in-Campus collaborations with VHIO have been strengthen and internalization of our research has been amplified. It is also noteworthy the shared scientific production in terms of publications between different groups of the Area and the stable collaborations between groups that have consolidated during these period.

Publications

174
total
926
impact factor
5.32
average impact factor

Group Leader: Simó Schwartz Navarro

The group of Drug Delivery and Targeting (DDT) studies the molecular pathways involved in cancer progression and in the physiopathology of certain low prevalent diseases, namely lysosomal storage disorders. With this gained knowledge, the objective of the group is to develop new treatment strategies, using either synthetic nanoparticles or naturally produced extracellular vesicles (EVs).

During 2020 DDT has deepen in the role of EVs in cancer and their potential use of as drug delivery systems (DDS) in different indications. Besides, we have extended our portfolio of DDS by including novel delivery system, by patenting new targeting moieties and by demonstrating that our systems are suitable for hard-to-deliver actives, such antibodies. These progresses are reflected in our active participation in national (3) and H2020 projects (4), relevant publications (9 in Q1), patents (1 new application, 2 advancing to National Phases) and the generation of a spin-off (BSURE) completed in January 2021.

VHIR Annual Report 2020